Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement
COPENHAGEN, Denmark; February 23, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.
Please find below a statement of such trading in shares issued by Genmab A/S
| 1. | Details of the person discharging managerial responsibilities / | ||
| a) | Name | Jan G. J. van de Winkel | |
| 2. | Reason for the notification | ||
| a) | Position/status | President & Chief Executive Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, | ||
| a) | Name | Genmab A/S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s): section to be repeated for | ||
| a) | Description of the financial | Restricted Stock Units related to shares of Genmab A/S | |
| b) | Nature of the transaction | Grant of Restricted Stock Units | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
|
|
| DKK 0.00 | 27,404 (annual equity award) |
| DKK 0.00 | 1,004 (deferred annual cash bonus) | ||
| d) | Aggregated information |
| |
| e) | Date of the transaction | 2024-02-23 | |
| f) | Place of the transaction | Outside the market | |
|
| Details of the person discharging managerial responsibilities / | ||
| a) | Name | Anthony Pagano | |
| 2. | Reason for the notification | ||
| a) | Position/status | Executive Vice President & Chief Financial Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, | ||
| a) | Name | Genmab A/S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s): section to be repeated for | ||
| a) | Description of the financial | Restricted Stock Units related to shares of Genmab A/S | |
| b) | Nature of the transaction | Grant of Restricted Stock Units | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
|
|
| DKK 0.00 | 13,043 (annual equity award) |
| DKK 0.00 | 286 (deferred annual cash bonus) | ||
| d) | Aggregated information |
| |
| e) | Date of the transaction | 2024-02-23 | |
| f) | Place of the transaction | Outside the market | |
| 1. | Details of the person discharging managerial responsibilities / | ||
| a) | Name | Martin Schultz | |
| 2. | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, | ||
| a) | Name | Genmab A/S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s): section to be repeated for | ||
| a) | Description of the financial | Restricted Stock Units related to shares of Genmab A/S | |
| b) | Nature of the transaction | Grant of Restricted Stock Units | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
|
|
| DKK 0.00 | 270 |
| d) | Aggregated information |
| |
| e) | Date of the transaction | 2024-02-23 | |
| f) | Place of the transaction | Outside the market | |
| 1. | Details of the person discharging managerial responsibilities / | ||
| a) | Name | Takahiro Hamatani | |
| 2. | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, | ||
| a) | Name | Genmab A/S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s): section to be repeated for | ||
| a) | Description of the financial | Restricted Stock Units related to shares of Genmab A/S | |
| b) | Nature of the transaction | Grant of Restricted Stock Units | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
|
|
| DKK 0.00 | 148 |
| d) | Aggregated information |
| |
| e) | Date of the transaction | 2024-02-23 | |
| f) | Place of the transaction | Outside the market | |
| 1. | Details of the person discharging managerial responsibilities / | ||
| a) | Name | Mijke Zachariasse | |
| 2. | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, | ||
| a) | Name | Genmab A/S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s): section to be repeated for | ||
| a) | Description of the financial | Restricted Stock Units related to shares of Genmab A/S | |
| b) | Nature of the transaction | Grant of Restricted Stock Units | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
|
|
| DKK 0.00 | 258 |
| d) | Aggregated information |
| |
| e) | Date of the transaction | 2024-02-23 | |
| f) | Place of the transaction | Outside the market | |
| 1. | Details of the person discharging managerial responsibilities / | ||
| a) | Name | Martin Schultz | |
| 2. | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, | ||
| a) | Name | Genmab A/S | |
| b) | LEI-code | N/A | |
| 4. | Details of the transaction(s): section to be repeated for | ||
| a) | Description of the financial | Warrants related to shares of Genmab A/S | |
| b) | Nature of the transaction | Grant of warrants | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
|
|
| DKK 0.00 | 277 |
| d) | Aggregated information |
| |
| e) | Date of the transaction | 2024-02-23 | |
| f) | Place of the transaction | Outside the market | |
| 1. | Details of the person discharging managerial responsibilities / | ||
| a) | Name | Takahiro Hamatani | |
| 2. | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, | ||
| a) | Name | Genmab A/S | |
| b) | LEI-code | N/A | |
| 4. | Details of the transaction(s): section to be repeated for | ||
| a) | Description of the financial | Warrants related to shares of Genmab A/S | |
| b) | Nature of the transaction | Grant of warrants | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
|
|
| DKK 0.00 | 152 |
| d) | Aggregated information |
| |
| e) | Date of the transaction | 2024-02-23 | |
| f) | Place of the transaction | Outside the market | |
| 1. | Details of the person discharging managerial responsibilities / | ||
| a) | Name | Mijke Zachariasse | |
| 2. | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, | ||
| a) | Name | Genmab A/S | |
| b) | LEI-code | N/A | |
| 4. | Details of the transaction(s): section to be repeated for | ||
| a) | Description of the financial | Warrants related to shares of Genmab A/S | |
| b) | Nature of the transaction | Grant of warrants | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
|
|
| DKK 0.00 | 265 |
| d) | Aggregated information |
| |
| e) | Date of the transaction | 2024-02-23 | |
| f) | Place of the transaction | Outside the market | |
About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO™) antibody medicines.
